Aurinia Pharmaceuticals Inc. (T:AUP*CA)

Business Focus: Bio Therapeutic Drugs

Apr 19, 2022 07:10 am ET
Aurinia Announces Year-Two Commitment to Patient Navigation Grant Program to Address Barriers for Individuals Living with Lupus and Lupus Nephritis
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today, affirmed its commitment to individuals living with the systemic lupus erythematosus (SLE) and lupus nephritis (LN) through the sponsorship of charitable grants to establish or expand community-focused patient navigator programs. This is the second year of th
Jul 26, 2021 06:05 am ET
Aurinia Pharmaceuticals to Release Second Quarter 2021 Financial Results on August 5, 2021
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that it will release its second quarter 2021 financial results on Thursday, August 5, 2021, after the markets close. Aurinia’s management team will also host a conference call at 4:30 p.m. EDT to discuss the Company’s financial results and to provide a general business update.
Jul 23, 2021 05:15 pm ET
S&P Dow Jones Indices Announces Changes to the S&P/TSX Composite Index
TORONTO, July 23, 2021 /CNW/ - S&P Dow Jones Indices announces the following changes to the S&P/TSX Composite Index:
Jul 16, 2021 05:30 pm ET
Aurinia Pharmaceuticals Announces Delisting from the Toronto Stock Exchange
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company), a commercial stage biopharmaceutical company advancing therapies for severe autoimmune diseases, announced today it will voluntarily delist the common shares of the Company from the Toronto Stock Exchange (TSX) effective as of the close of trading on Ju
Jun 14, 2021 06:05 am ET
Aurinia Announces Addition of Dr. Brinda Balakrishnan to the Board of Directors
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) announced today the appointment of Dr. Brinda Balakrishnan, M.D., Ph.D., to the Company’s Board of Directors effective June 14, 2021. Dr. Balakrishnan is Group Vice President, Corporate and Business Development of BioMarin Pharmaceutical Inc. (“BioMarin”
Jun 07, 2021 07:05 pm ET
Aurinia Announces Results of the 2021 Annual General Meeting
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”) is pleased to announce that the eight incumbent directors of the Company were elected at the Company’s annual general meeting (the “Meeting”) held on June 7, 2021.
Jun 07, 2021 07:04 am ET
Aurinia Announces Additional Analysis of its AURORA 1 Phase 3 Study Data Presented at ERA-EDTA 2021 Congress
In the assessment presented at ERA-EDTA, researchers conducted a sensitivity study evaluating renal response (RR) with additional urine protein creatinine ratio (UPCR) targets given the efficacy demonstrated of voclosporin in terms of proteinuria reduction in the AURORA 1 study. This examination demonstrated that patients treated with voclosporin in addition to mycophenolate mofetil (MMF) and low-dose steroids achieved statistically significant increased renal response rates regardless of the level of UPCR, including at an even more stringent ≤0.3 mg/mg target. The data further support the eff
May 27, 2021 06:05 am ET
Aurinia Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the executive management team will participate in a fireside chat during the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 11:30 a.m. ET.
May 20, 2021 04:05 pm ET
Aurinia To Present Supportive AURORA 2 Continuation Study Interim Analysis Demonstrating Long-Term Safety & Efficacy of LUPKYNIS™ (voclosporin) in Subjects with Lupus Nephritis
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) announced today that a supportive interim analysis of its AURORA 2 continuation study will be presented at the upcoming European Alliance of Associations for Rheumatology (EULAR) 2021 Congress June 2-5, 2021.
May 14, 2021 06:05 am ET
Aurinia Pharmaceuticals to Participate in Two Upcoming Investor Conferences
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the executive management team will participate in two upcoming investor conferences:
May 10, 2021 04:05 pm ET
Aurinia Unveils Patient Navigation Grant Program to Address Access Barriers for Individuals Living with Lupus and Lupus Nephritis
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) today, in recognition of World Lupus Day, affirmed its commitment to increasing access to equitable healthcare for individuals living with the autoimmune disease systemic lupus erythematosus (SLE) and lupus nephritis (LN) through the sponsorship of grant
May 10, 2021 06:05 am ET
Aurinia Announces Publication of AURORA 1 Phase 3 Study Results with LUPKYNIS™ (voclosporin) in The Lancet
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”) today announced that
May 06, 2021 04:05 pm ET
Aurinia Reports First Quarter 2021 Financial Results and Recent Operational Highlights
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”) today issued its financial results for the first quarter ended March 31, 2021. Amounts, unless specified otherwise, are expressed in U.S. dollars.
Apr 28, 2021 06:30 am ET
Aurinia Pharmaceuticals to Release First Quarter 2021 Financial Results on May 6, 2021
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that it will release its first quarter 2021 financial results on Thursday, May 6, 2021, after the markets close. Aurinia’s management team will also host a conference call at 5:00 p.m. EDT to discuss the Company’s financial results and to provide a general business update.
Apr 15, 2021 06:05 am ET
Aurinia Pharmaceuticals to Present at the Bloom Burton & Co. Healthcare Investor Conference
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the executive management team will participate in a fireside chat during the 2021 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 20, 2021 at 2:30 p.m. ET.
Apr 08, 2021 06:05 am ET
Aurinia Presents Data Demonstrating LUPKYNIS™ (voclosporin) Efficacy Across Lupus Nephritis Biopsy Classes at National Kidney Foundation 2021 Spring Clinical Meetings
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) today presented additional efficacy data from the AURA-LV and AURORA 1 pivotal trials of LUPKYNIS™ (voclosporin) in lupus nephritis (LN). The data were shared at the National Kidney Foundation (NKF) 2021 Spring Clinical Meetings by Anca D. Askanas
Mar 15, 2021 06:05 am ET
Aurinia Announces Positive Cost-Effectiveness Assessment of LUPKYNIS™ (voclosporin) in Latest ICER Draft Evidence Report
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) today announced a favorable assessment regarding the cost-effectiveness and value of LUPKYNIS™ (voclosporin), based on an independent analysis issued by the Institute for Clinical and Economic Review (ICER) in a revised
Mar 02, 2021 06:05 am ET
Aurinia Pharmaceuticals to Present at Three Upcoming March Investor Conferences
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the executive management team will participate in multiple upcoming investor conferences including the:
Feb 24, 2021 04:02 pm ET
Aurinia Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Operational Highlights
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”) today issued its financial results for the fourth quarter and year ended December 31, 2020. Amounts, unless specified otherwise, are expressed in U.S. dollars.
Feb 18, 2021 06:05 am ET
Aurinia Pharmaceuticals to Present at the SVB Leerink 10th Annual Global Healthcare Conference
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the executive management team will participate in a fireside chat at the (virtual) SVB Leerink 10th Annual Global Healthcare Conference on Thursday, February 25, 2021 at 1:00 p.m. ET.
Feb 17, 2021 06:05 am ET
Aurinia Pharmaceuticals to Release Fourth Quarter and Year End 2020 Financial Results on February 24, 2021
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that it will release its fourth quarter and year end 2020 financial results on Wednesday, February 24, 2021, after the markets close. Aurinia’s management team will host a conference call to discuss the Company’s financial results and to provide a general business update.
Jan 22, 2021 08:24 pm ET
FDA Approves Aurinia Pharmaceuticals’ LUPKYNIS™ (voclosporin) for Adult Patients with Active Lupus Nephritis
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved LUPKYNISTM (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult patients with active lupus nephritis (LN). LUPKYNIS is
Jan 08, 2021 06:05 am ET
Aurinia Pharmaceuticals to Present at Two Upcoming Virtual Healthcare Conferences
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the management team will participate in two upcoming virtual investor conferences and participate in a panel discussion hosted by Dr. Scott Gottlieb, former FDA Commissioner:
Dec 17, 2020 04:00 am ET
Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”) today announced it has entered into a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. for the development and commercialization of oral voclosporin for the treatment of Lupus Nephritis (LN) in the European Union (EU), Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine.
Dec 15, 2020 05:59 pm ET
Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia”) and Lonza Ltd. (SIX: LONN) ("Lonza") today announced they have expanded their exclusive manufacturing relationship. The parties entered into a collaborative agreement to build a dedicated manufacturing capacity within Lonza’s existing small molecule API facility in Visp, Switzerland. The dedicated facility (also referred to as "monoplant") will be equipped with state-of-the-art manufacturing equipment to provide cost and production efficiency for the manufacture of voclosporin, while expanding existing capacity an
Dec 02, 2020 06:05 am ET
Aurinia Pharmaceuticals to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced its participation in the Piper Sandler 32nd Annual Virtual Healthcare Conference. Presentations will be available for registered attendees via the Piper Sandler conference site through December 3.
Nov 12, 2020 04:05 pm ET
Aurinia Pharmaceuticals to Present at the 2020 Jefferies Virtual London Healthcare Conference
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the senior management team will participate in a fireside chat during the 2020 Jefferies Virtual London Healthcare Conference on November 19, 2020 at 11:25 a.m. ET.
Nov 10, 2020 04:02 pm ET
Aurinia Reports Third Quarter 2020 Financial Results and Recent Operational Highlights
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”) today reported financial results for the third quarter ended September 30, 2020 and provided an update on recent operational highlights. Amounts, unless specified otherwise, are expressed in U.S. dollars.
Nov 09, 2020 04:05 pm ET
Aurinia Presents Integrated Time to Renal Response Data from the AURA-LV and AURORA Trials, along with Voclosporin Drug-Drug Interaction Data at ACR Convergence 2020
Aurinia Pharmaceuticals Inc. (Nasdaq: AUPH / TSX:AUP) (Aurinia or the Company), a late-stage clinical biopharmaceutical company, today announced data from an integrated analysis of the AURA-LV and AURORA pivotal trials that further supports voclosporin as a potential treatment for lupus nephritis (LN) in a presentation at the American College of Rheumatology (ACR) Convergence 2020. The Company also shared data from a clinical drug-drug interaction (DDI) study in patients with systemic lupus erythematosus (SLE), showing that voclosporin does not have a meaningful drug-drug interaction when admi
Nov 02, 2020 04:05 pm ET
Aurinia Announces Outcome of AUDREY™ Clinical Trial in Dry Eye Syndrome
Aurinia Pharmaceuticals Inc. (Nasdaq: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company, today announced topline data from the Phase 2/3 AUDREY™ clinical study evaluating voclosporin ophthalmic solution (VOS) for the potential treatment of dry eye syndrome (DES). The trial did not achieve statistical significance on its primary endpoint of a 10mm or greater improvement in STT at four weeks between active dose groups of VOS compared to vehicle. Aurinia is suspending the development program for VOS based upon these results.
Oct 27, 2020 04:05 pm ET
Aurinia Announces European Investigator-Initiated Trial to Evaluate Antiviral Activity of Voclosporin in Kidney Transplant Recipients with COVID-19
Voclosporin is a novel calcineurin inhibitor (CNI) developed to treat patients with lupus nephritis. By inhibiting calcineurin, voclosporin blocks IL-2 expression and reduces T-cell mediated immune responses while it synergistically stabilizes podocytes in the kidney. This novel CNI has a favorable metabolic profile and a consistent, predictable dose response potentially eliminating the need for therapeutic drug monitoring.
Oct 22, 2020 04:15 pm ET
Aurinia Presents Voclosporin Efficacy and Pharmacokinetic Data from Integrated Analysis of AURA-LV and AURORA Pivotal Trials at ASN Kidney Week 2020
Aurinia Pharmaceuticals Inc. (Nasdaq:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications, today announced that integrated efficacy and pharmacokinetic (PK) data from Aurinia’s AURA-LV and AURORA pivotal trials of voclosporin in lupus nephritis (LN) were presented. The data were shared at the American Society of Nephrology (ASN) Kidney Week 2020 in presentations given by Brad Rovin, M.D., FASN, Director of Nephrology and Vice Chairman of Research for the Department of Internal Medicine at the
Oct 14, 2020 06:05 am ET
Aurinia Pharmaceuticals Announces Launch of Lupus Nephritis Disease-State Awareness Initiative for Healthcare Professionals, TimeIsNephrons.com
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”) today announced Time Is Nephrons, the first-ever lupus nephritis (LN) disease-state awareness campaign for healthcare professionals (HCPs). The initiative aims to highlight the importance of active screening for early diagnosis to potentially minimize the impact on kidney function and improve long-term outcomes for every patient with LN.
Sep 28, 2020 06:05 am ET
Aurinia Completes Final Patient Treatment in AUDREY Phase 2/3 Clinical Trial of Voclosporin Ophthalmic Solution for Dry Eye Syndrome
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (Aurinia or the Company), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple autoimmune conditions, today announced that the last patient study visit has occurred in the Phase 2/3 AUDREY™ clinical study evaluating voclosporin ophthalmic solution (VOS) for the potential treatment of dry eye syndrome (DES).
Sep 10, 2020 06:05 am ET
Aurinia Pharmaceuticals to Present at Three Upcoming Virtual Investor Conferences
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the senior management team will participate in fireside chats during the following upcoming virtual investor conferences:
Aug 11, 2020 04:02 pm ET
Aurinia Reports Second Quarter 2020 Financial Results and Recent Operational Highlights
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (Aurinia or the Company) today reported financial results for the second quarter ended June 30, 2020 and provided an update on recent operational highlights.
Aug 04, 2020 06:05 am ET
Aurinia Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that Peter Greenleaf, President and Chief Executive Officer of Aurinia, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Monday, August 10, 2020 at 11:00 a.m. EDT.
Jul 30, 2020 06:05 am ET
Aurinia Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 11, 2020
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that it will release its second quarter 2020 financial results on Tuesday, August 11, 2020, after the markets close. Aurinia’s executive team will host a conference call to discuss the Company’s financial results and to provide a general business update.
Jul 27, 2020 10:15 am ET
Aurinia Closes US$200 Million Public Offering of Common Shares
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced the closing of its previously announced underwritten public offering of 13,333,334 common shares (the “Offering”). The shares were sold at a public offering price of US$15.00 per share. The gross offering proceeds to the Company from this Offering are approximately US$200 million, before deducting underwriting discounts and commissions and other offering expenses.
Jul 22, 2020 11:05 pm ET
Aurinia Prices US$200 Million Public Offering of Common Shares
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced the pricing of its underwritten public offering of 13,333,334 common shares (the “Offering”). The shares are being sold at a public offering price of US$15.00 per share. The gross offering proceeds to the Company from this Offering are expected to be approximately US$200 million, before deducting underwriting discounts and commissions and other offering expenses. All of the shares are being o
Jul 22, 2020 04:08 pm ET
Aurinia Announces Public Offering of Common Shares
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced that it has commenced a registered underwritten public offering of its common shares (the “Offering”).
Jul 21, 2020 05:27 pm ET
Aurinia Announces U.S. Food and Drug Administration Acceptance of the Filing of New Drug Application and Priority Review for Voclosporin for the Treatment of Lupus Nephritis
Aurinia Pharmaceuticals Inc. (Nasdaq:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications, today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of its New Drug Application (NDA) for voclosporin, as a potential treatment for lupus nephritis (LN), a serious inflammation of the kidneys caused by the autoimmune disease systemic lupus erythematosus (SLE). The FDA has granted Priority Review for the NDA, which provides an expedited six month review, and has assign
Jun 22, 2020 06:05 am ET
Aurinia Completes Patient Enrollment Into the AUDREY Phase 2/3 Clinical Trial of Voclosporin Ophthalmic Solution for the Treatment of Dry Eye Syndrome
Aurinia Pharmaceuticals Inc. (Nasdaq: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications, today announced it has completed enrollment for the Phase 2/3 AUDREY™ clinical trial evaluating voclosporin ophthalmic solution (VOS) for the potential treatment of dry eye syndrome (DES), a chronic disease estimated to affect more than 16 million people in the United States.
Jun 12, 2020 05:15 pm ET
S&P Dow Jones Indices Announces Changes to the S&P/TSX Composite Index and S&P/TSX 60 Index
TORONTO, June 12, 2020 /CNW/ - As a result of the quarterly review, S&P Dow Jones Indices will make the following changes in the S&P/TSX Composite Index and S&P/TSX 60 Index prior to the open of trading on Monday, June 22, 2020:
Jun 09, 2020 06:05 am ET
Aurinia Presents Additional AURORA Pivotal Trial Safety Data at the ERA-EDTA Virtual Congress 2020
Aurinia Pharmaceuticals Inc. (Nasdaq:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications, announced that additional safety data from the completed AURORA pivotal trial of voclosporin were shared at the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) 2020 Virtual Congress in an oral presentation given by nephrologist Dawn Caster, M.D., Assistant Professor of Medicine at the University of Louisville School of Medicine.
Jun 03, 2020 06:05 am ET
Aurinia Announces Results of Annual General Meeting
All other matters voted on at the Meeting were also approved. Voting results on all matters voted on at the Meeting will be filed on SEDAR at www.sedar.com and EDGAR at
Jun 01, 2020 04:05 pm ET
Aurinia Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that Peter Greenleaf, President and Chief Executive Officer of Aurinia, will participate in a fireside chat during the 2020 Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 3:30 p.m. EDT.
May 15, 2020 04:05 pm ET
Aurinia Pharmaceuticals to Present at 2020 RBC Capital Markets’ Virtual Global Healthcare Conference
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that Peter Greenleaf, President and Chief Executive Officer of Aurinia, will participate in a fireside chat during the 2020 RBC Capital Markets’ Virtual Global Healthcare Conference on Tuesday, May 19, 2020 at 10:20 a.m. E.D.T.
May 14, 2020 04:02 pm ET
Aurinia Reports First Quarter 2020 Financial Results and Recent Operational Highlights
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”) today reported financial results for the first quarter ended March 31, 2020 and provided an update on recent operational highlights. Amounts, unless specified otherwise, are expressed in U.S. dollars.
May 07, 2020 06:05 am ET
Aurinia Pharmaceuticals to Release First Quarter 2020 Financial Results on May 14, 2020
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the “Company”) today announced that it will release its first quarter 2020 financial results on Thursday, May 14, 2020, after the markets close. Aurinia’s management team will host a conference call to discuss the Company’s financial results and to provide a general business update.
Apr 27, 2020 06:05 am ET
Aurinia Appoints Joe Miller as Chief Financial Officer
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced the appointment of Joe Miller as Chief Financial Officer. Mr. Miller will be responsible for developing and leading the Company’s financial operations to effectively support the Company’s rapid growth. Dennis Bourgeault will be retiring from that role after serving the Company for more than two decades.
Mar 17, 2020 06:00 am ET
Aurinia Pharmaceuticals Establishes U.S. Commercial Operations Center in Rockville, Maryland
“We are thrilled to announce the opening of our U.S. commercial offices in Montgomery County, Maryland, as we continue to advance the development of voclosporin, which has the potential to become the first-ever approved treatment for patients suffering from lupus nephritis. This important milestone follows the recent build-out of our commercial leadership team, as we move swiftly, yet responsibly, toward commercial readiness,” said Peter Greenleaf, President and Chief Executive Officer of Aurinia. “Maryland’s commitment to attracting and supporting leading innovators played a key role in our d
Mar 16, 2020 06:05 am ET
Aurinia Pharmaceuticals Initiates Rolling Submission of a New Drug Application to the U.S. Food and Drug Administration for Voclosporin in the Treatment of Lupus Nephritis
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, announced today that the Company has initiated a Rolling Submission of its New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for voclosporin, a next-generation calcineurin inhibitor for the treatment of lupus nephritis (“LN”). The rolling NDA allows completed portions of an NDA to be submitted and reviewed by the Agency on an ongoing basis. Aurinia has submitted the Nonclinical Mo
Mar 12, 2020 07:00 am ET
Aurinia Launches Resource Kit for People Living With Lupus Nephritis and Partners With National Kidney Foundation on Awareness Initiative
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”) , a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory and autoimmune conditions, today announced new initiatives to support the lupus nephritis (LN) community and raise disease awareness on World Kidney Day, during National Kidney Month and beyond. These initiatives and resources include:
Mar 05, 2020 04:02 pm ET
Aurinia Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX: AUP) (“Aurinia” or the “Company”) today issued its financial results for the fourth quarter and year ended December 31, 2019. Amounts, unless specified otherwise, are expressed in U.S. dollars.
Mar 03, 2020 06:30 am ET
Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year 2019 Financial Results on March 5, 2020
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that it will release its fourth quarter and full year 2019 financial results on Thursday, March 5, 2020, after the markets close. Aurinia’s management team will host a conference call to discuss the Company’s financial results and to provide a general business update.
Feb 25, 2020 06:30 am ET
Aurinia Appoints Max Colao as Chief Commercial Officer and Expands U.S. Commercial Leadership Team
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced the appointment of Max Colao to the newly created position of Chief Commercial Officer. In addition, Aurinia has recruited an experienced team of leaders across key commercial functions including sales, marketing, market access, and commercial operations.
Feb 21, 2020 04:05 pm ET
Aurinia Pharmaceuticals to Present at the 9th Annual SVB Leerink Global Healthcare Conference
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the “Company”) today announced that Mr. Peter Greenleaf, President and Chief Executive Officer, will present a corporate overview at the 9th Annual SVB Leerink Global Healthcare Conference on Tuesday, February 25, 2019 at 10:00 a.m. ET in New York, NY.
Dec 12, 2019 09:26 am ET
Aurinia Closes US$191.7 Million Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Common Shares
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced the closing of its previously announced underwritten public offering of 12,782,439 common shares, including 1,667,274 common shares pursuant to the full exercise of the underwriters’ option to purchase additional common shares (the “Offering”). The shares were sold at a public offering price of US$15.00 per share. The gross offering proceeds to the Company from this Offering are approximately
Dec 09, 2019 09:00 pm ET
Aurinia Prices US$166.7 Million Public Offering of Common Shares
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced the pricing of its underwritten public offering of 11,115,165 common shares (the “Offering”). The shares are being sold at a public offering price of US$15.00 per share. The gross offering proceeds to the Company from this Offering are expected to be approximately US$166.7 million, before deducting underwriting discounts and commissions and other estimated offering expenses. All of the shares
Dec 09, 2019 06:01 am ET
Aurinia Announces Public Offering of Common Shares
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced that it has commenced a registered underwritten public offering of US$150,000,000 of its common shares (the “Offering”).
Dec 05, 2019 07:16 am ET
IIROC Trade Resumption - AUP
TORONTO, Dec. 5, 2019 /CNW/ - Trading resumes in:
Dec 04, 2019 04:05 pm ET
Aurinia Announces Positive AURORA Phase 3 Trial Results Demonstrating Voclosporin Superiority Over Standard of Care in Lupus Nephritis
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory and autoimmune conditions, today announced positive efficacy and safety results from its pivotal AURORA Phase 3 trial of voclosporin, in combination with mycophenolate (“MMF”) and low-dose corticosteroids, in the treatment of lupus nephritis (“LN”).
Dec 04, 2019 03:22 pm ET
IIROC Trading Halt - AUP
TORONTO, Dec. 4, 2019 /CNW/ - The following issues have been halted by IIROC:
Dec 03, 2019 06:30 am ET
Aurinia to Present Preclinical Voclosporin Data at 2020 Keystone Symposia Conference
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory and autoimmune conditions, today announced that an abstract has been accepted for presentation at the Keystone Symposia Conference on Islet Biology: From Gene to Cell to Micro-Organ in Santa Fe, New Mexico from January 27-31, 2020. The abstract will be presented by Dr. James D. Johnson, Professor of Medicine in the Department of Cellular and Physiological Sciences and the Department of Surgery at the Un
Nov 14, 2019 04:02 pm ET
Aurinia Reports Third Quarter 2019 Financial Results and Recent Operational Highlights
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today reported financial results for the three and nine months ended September 30, 2019 and recent operational highlights. Amounts, unless specified otherwise, are expressed in U.S. dollars.
Nov 13, 2019 04:05 pm ET
Aurinia Announces Updates to the Board of Directors
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory and autoimmune conditions, today announced the appointment of Ms. Jill Leversage to its Board of Directors and the resignation of Dr. Hyeuk Joon Lee.
Nov 07, 2019 06:30 am ET
Aurinia Completes Voclosporin Drug-Drug Interaction Study Demonstrating No Clinically Significant Interaction With Mycophenolate Mofetil
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory and autoimmune conditions, today announced the completion of a FDA-requested clinical drug-drug interaction (“DDI”) study in patients with lupus that investigated the potential effect of voclosporin on blood levels of mycophenolate acid (“MPA”), the active metabolite of mycophenolate mofetil (“MMF”). MMF, also known as CellCept®, is considered by treating physicians to be part of the current standard of
Nov 06, 2019 04:05 pm ET
Aurinia Pharmaceuticals to Release Third Quarter 2019 Financial Results on November 14, 2019
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that it will release its third quarter 2019 financial results on Thursday, November 14, 2019, after the market closes. Aurinia’s management team will host a conference call to discuss the Company’s financial results and to provide a general business update.
Oct 31, 2019 06:30 am ET
Aurinia Announces Initiation of Patient Dosing in Phase 2/3 AUDREY™ Clinical Trial for Dry Eye Syndrome
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory and autoimmune conditions, today announced the initiation of patient dosing in the Phase 2/3 AUDREY™ clinical trial evaluating voclosporin ophthalmic solution (“VOS”) for the potential treatment of dry eye syndrome (“DES”).
Oct 16, 2019 06:30 am ET
Aurinia Reports Last Patient Study Visit in Aurora Phase 3 Lupus Nephritis Study and Provides Update on ATM Facility
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory and autoimmune conditions, today reported that the last patient study visit has occurred in the AURORA Phase 3 lupus nephritis (“LN”) study. Efficacy and safety results from AURORA remain on track to be reported by the end of the fourth quarter 2019.
Sep 26, 2019 04:05 pm ET
Aurinia Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the “Company”) today announced that Peter Greenleaf, President and Chief Executive Officer of Aurinia, will participate in a fireside chat at the 2019 Cantor Global Healthcare Conference on Wednesday, October 2, 2019 at 1:15 p.m. ET in New York, NY.
Sep 13, 2019 05:11 pm ET
Aurinia Establishes At-the-Market Facility
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late- stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced that it has entered into an Open Market Sales Agreement with Jefferies LLC (“Jefferies”) pursuant to which the Company may from time to time sell, through at-the-market (“ATM”) offerings with Jefferies acting as sales agent, such common shares as would have an aggregate offer price of up to US$40,000,000. Aurinia has also filed a prospectus supplement with securities regulatory authorities
Sep 06, 2019 06:05 am ET
Aurinia Pharmaceuticals to Present at the 21st Annual H.C. Wainwright Global Investment Conference
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the “Company”) today announced that Peter Greenleaf, President and Chief Executive Officer of Aurinia, will present a corporate overview at the 21st Annual H.C. Wainwright Global Investment Conference on Monday, September 9, 2019 at 12:30pm ET in New York, NY.
Aug 06, 2019 04:02 pm ET
Aurinia Reports Second Quarter 2019 Financial Results and Operational Highlights
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late- stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today reported financial results for the three and six months ended June 30, 2019 and recent operational highlights. Amounts, unless specified otherwise, are expressed in U.S. dollars.
Aug 01, 2019 06:30 am ET
Aurinia Pharmaceuticals to Release Second Quarter 2019 Financial Results on August 6, 2019
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the “Company”) today announced that it will release its second quarter 2019 financial results on Tuesday, August 6, 2019, after the market closes. Aurinia’s management team will host a conference call to discuss the company’s financial results and to provide a general business update.
Jul 18, 2019 06:30 am ET
Aurinia Announces Further Strengthening of the Senior Management Team
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH/TSX: AUP) (the “Company”), a late-stage clinical biopharmaceutical company with ongoing research in lupus nephritis (“LN”), today announced the appointments of Mr. Max Donley as Executive Vice President of Internal Operations and Strategy and Dr. Glenn Schulman as Senior Vice President of Corporate Communications and Investor Relations.
Jun 27, 2019 08:02 am ET
ILJIN Comments on Aurinia Pharmaceutical’s Annual Meeting
ILJIN SNT Co., Ltd. (“ILJIN”), a founding shareholder of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH, TSX: AUP) (“Aurinia” or the “Corporation”), which together with certain affiliates holds an approximate 14% ownership interest in Aurinia, today commented on the voting results of the Aurinia annual meeting of shareholders.
Jun 26, 2019 07:00 pm ET
Aurinia Shareholders Elect all Eight Directors at 2019 Annual General Meeting
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”) is pleased to announce that shareholders of the Company (the “Shareholders”) elected all eight of the Company’s highly qualified director nominees at the Company’s Annual General Meeting held on June 26, 2019 (the “Meeting”).
Jun 21, 2019 07:59 am ET
ILJIN Chairman Issues Open Letter to Aurinia Shareholders
ILJIN SNT Co., Ltd. (“ILJIN”), a founding shareholder of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH, TSX: AUP) (“Aurinia” or the “Corporation”), which together with certain affiliates holds an approximate 14% ownership interest in Aurinia, today issued an open letter to Aurinia shareholders from ILJIN Group Chairman, Mr. Chin Kyu Huh.
Jun 21, 2019 06:30 am ET
Aurinia Reminds Shareholders to Vote the YELLOW Proxy Prior to June 24 Deadline
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”) today reminded shareholders to vote in advance of the proxy voting deadline of 10:00 AM Mountain Time on Monday, June 24, 2019. Aurinia urges shareholders to vote the YELLOW proxy in support of management’s nominees.
Jun 20, 2019 08:00 am ET
As Deadline Approaches ILJIN SNT Reminds Aurinia Shareholders to Vote the GREEN Proxy for Nominees Committed to Correcting Governance Failures and to Realizing Aurinia’s Full Potential
ILJIN SNT Co., Ltd. (“ILJIN”), a founding shareholder of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH, TSX: AUP) (“Aurinia” or the “Corporation”), which together with certain affiliates holds an approximate 14% ownership interest in Aurinia, today thanks shareholders for their support ahead of the upcoming Annual General Meeting of Shareholders and encourages all shareholders who haven’t yet voted to vote their GREEN proxy today for the director nominees who are aligned with their interests and are committed to the future success of the company.
Jun 19, 2019 06:30 am ET
Leading Independent Proxy Advisors Recommend Aurinia Shareholders Vote the YELLOW Proxy Card FOR All of Aurinia’s Director Nominees
Leading independent proxy advisory firms Institutional Shareholder Services Inc. (“ISS”) and Glass Lewis & Co. (“Glass Lewis”) have recommended shareholders of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”) vote the YELLOW proxy card in support of ALL of the Company’s nominees in advance of the upcoming Annual General Meeting of Shareholders (the “AGM”) to be held on Wednesday, June 26, 2019. Shareholders of record as of May 9, 2019 must submit their YELLOW proxy by 10:00 AM Mountain Time on Monday, June 24,
Jun 12, 2019 08:00 am ET
ILJIN SNT Files Investor Presentation, Urging Aurinia Shareholders to Correct Governance Failures and Director Conflicts
ILJIN SNT Co., Ltd. (“ILJIN”), a founding shareholder of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH, TSX: AUP) (“Aurinia” or the “Corporation”), which together with certain affiliates holds an approximate 14% ownership interest in Aurinia, today filed an investor presentation on SEDAR in connection with the Corporation’s upcoming Annual General Meeting of Shareholders to be held on Wednesday, June 26, 2019. The investor presentation is also available at
Jun 10, 2019 02:58 pm ET
ILJIN SNT Sends Letter to Shareholders of Aurinia Highlighting Governance Failures and Director Conflicts and Responding to Misleading Information
ILJIN SNT Co., Ltd. (“ILJIN”) today sent a letter to shareholders of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH, TSX:AUP) (“Aurinia” or the “Corporation”), highlighting the governance failures and director conflicts under the current board of directors, correcting misleading information disseminated to shareholders by Aurinia on June 7, 2019 and urging shareholders to vote their GREEN proxy or GREEN VIF to strengthen the board.
Jun 07, 2019 08:00 am ET
Aurinia Issues Letter to Shareholders
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the “Company”) today sent a letter to shareholders in connection with the Company’s upcoming Annual General Meeting of Shareholders (“AGM”) to be held on Wednesday, June 26, 2019. Shareholders of record as of May 9, 2019 must submit their YELLOW proxy by 10:00 AM Mountain Time on Monday, June 24, 2019.
Jun 04, 2019 04:05 pm ET
Aurinia Pharmaceuticals to Present at Upcoming Investor Conferences
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the “Company”) today announced that Mr. Peter Greenleaf, Chief Executive Officer, will present a corporate overview at the following upcoming investor conferences:
Jun 03, 2019 03:09 pm ET
Largest Shareholder of Aurinia Pharmaceuticals, ILJIN SNT, Files Proxy Circular and Issues Letter to Fellow Shareholders
ILJIN SNT Co., Ltd. (“ILJIN”) today announced that it has filed an information circular (the "Circular") and letter to shareholders in connection with the upcoming Annual General Meeting of Shareholders of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH, TSX: AUP) (“Aurinia” or the “Corporation”) to be held on Wednesday, June 26, 2019.
May 31, 2019 08:30 am ET
Aurinia Pharmaceuticals Announces Upcoming Annual General Meeting of Shareholders
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”), today filed its Notice of Meeting and Management Information Circular. Aurinia plans to host its upcoming Annual General Meeting of Shareholders (“AGM”) at 10:00 a.m. MT on Wednesday, June 26, 2019, at the Westin Calgary, 320 4th Ave SW in Calgary, Alberta.
May 17, 2019 04:02 pm ET
Aurinia Pharmaceuticals to Present at the RBC Capital Markets Global Healthcare Conference
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the “Company”) today announced that Mr. Peter Greenleaf, Chief Executive Officer, will present a corporate overview at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 22, 2019 at 6:30am PT (9:30am ET) in New York, NY.
May 14, 2019 04:02 pm ET
Aurinia Reports First Quarter 2019 Financial Results and Recent Operational Highlights
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”) today reported financial results for the first quarter ended March 31, 2019 and provided an update on recent operational highlights. Amounts, unless specified otherwise, are expressed in U.S. dollars.
May 10, 2019 07:00 am ET
Aurinia Recognizes World Lupus Day and Lupus Awareness Month with Activities Focused on Raising Awareness for Lupus Nephritis
In recognition of Lupus Awareness Month and World Lupus Day, Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP) (the “Company”) a late clinical-stage biopharmaceutical company with ongoing research in lupus nephritis (“LN”), today recognized World Lupus Day and Lupus Awareness Month with the launch of awareness and educational initiatives to support people with LN and Systemic Lupus Erythematosus (“SLE”):
May 09, 2019 04:05 pm ET
Aurinia Pharmaceuticals to Release First Quarter 2019 Financial Results on May 14, 2019
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the “Company”) today announced that it will release its first quarter 2019 financial results on Tuesday, May 14, 2019, after the market closes. Aurinia’s management team will host a conference call to discuss the company’s financial results and to provide a general business update.
Apr 30, 2019 06:05 am ET
Aurinia Further Strengthens Its Board of Directors with the Appointment of Dr. Daniel Billen
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced it has appointed Dr. Daniel Billen to its Board of Directors. Dr. Billen’s appointment is effective April 29, 2019 concurrent with the previously announced appointment of Mr. Peter Greenleaf as Chief Executive Officer and elevation of Dr. George Milne to Chairman of the Board.
Apr 24, 2019 04:05 pm ET
Aurinia Pharmaceuticals to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the “Company”) today announced that members of the management team will present a corporate overview at the 2019 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 30, 2019 at 8:30am PT (11:30am ET) in Toronto, Ontario.
Apr 11, 2019 04:30 pm ET
Aurinia Announces Appointment of Peter Greenleaf as Chief Executive Officer and Board Director and the Elevation of Dr. George M. Milne, Jr. to Chairman of the Board
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”), a late clinical-stage biopharmaceutical company focused on the global immunology market, today announced the appointment of Mr. Peter Greenleaf as Chief Executive Officer and as a Director on the Aurinia Board. The Company also announced the elevation of George M. Milne, Jr., Ph.D. to Chairman of the Board of Directors. Dr. Richard M. Glickman, who previously announced his plans to retire on November 6, 2018, will step down from his role as Chairman and CEO conc
Mar 19, 2019 04:02 pm ET
Aurinia Reports Fourth Quarter and Full Year 2018 Financial Results and Operational Highlights
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”) today reported its financial results for the fourth quarter and year ended December 31, 2018. Amounts, unless specified otherwise, are expressed in U.S. dollars.
Mar 14, 2019 07:00 am ET
Aurinia Recognizes World Kidney Day and National Kidney Month with New Activities Focused on Raising Awareness for Kidney Disease
In recognition of World Kidney Day and National Kidney Month, Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH/TSX: AUP), a late clinical-stage biopharmaceutical company with research ongoing in two kidney diseases, Lupus Nephritis (LN) and Focal Segmental Glomerulosclerosis (FSGS), today announced a host of activities, including an initiative with The National Kidney Foundation (NKF), designed to raise awareness for kidney disease. To find out more and to get involved in National Kidney Month, Aurinia invites all to:
Mar 07, 2019 04:05 pm ET
Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year 2018 Financial Results on March 19, 2019
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the “Company”) today announced that it will release its fourth quarter and full year 2018 financial results on Tuesday, March 19, 2019, after the market closes. Aurinia’s management team will host a conference call to discuss the company’s financial results for the fourth quarter and full year 2018 and to provide a general business update.
Feb 27, 2019 06:30 am ET
Aurinia Closes At-The-Market Facility
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the “Company”) today announced that, further to its Open Market Sale Agreement with Jefferies LLC previously disclosed on November 30, 2018, in relation to at-the-market (“ATM”) offerings of common shares in the capital of the Company, the Company has completed the sale of 4,608,409 common shares at a weighted average price of US$6.55 for aggregate gross proceeds of approximately US$30 million. No further sales will be conducted pursuant to the ATM.
Feb 25, 2019 07:00 am ET
Aurinia Receives Notice of Allowance from the US Patent and Trademark Office for Claims Directed to Its Novel Voclosporin Dosing Protocol for Lupus Nephritis
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/ TSX:AUP) (the “Company” or “Aurinia”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (“USPTO”) for U.S. patent application 15/835,219, entitled “PROTOCOL FOR TREATMENT OF LUPUS NEPHRITIS”. The allowed claims broadly cover the novel voclosporin dosing protocol adhered to and required in both the previously reported Phase II AURA-LV study and the ongoing Phase
Feb 20, 2019 04:01 pm ET
Aurinia to Present at the 8th Annual SVB Leerink Global Healthcare Conference New York City
Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced its Chairman and Chief Executive Officer, Richard M. Glickman, will present a corporate overview at the 8th Annual SVB Leerink Global Healthcare Conference in NYC on February 27, 2019 at 2:30pm ET.
Jan 22, 2019 07:00 am ET
Aurinia Announces Voclosporin Ophthalmic Solution Demonstrates Statistically Superior Efficacy Versus Restasis® in a Phase 2 Head-to-Head Study for the Treatment of Dry Eye Syndrome
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced positive results for its exploratory Phase 2 head-to-head study evaluating the efficacy, safety and tolerability of voclosporin ophthalmic solution (VOS 0.2%) versus Restasis®(cyclosporine ophthalmic emulsion 0.05%) for the treatment of dry eye syndrome (DES). Both drugs were shown to be well-tolerated and there was no statistical difference between VOS and Restasis® for the primary endpoint as b
Jan 21, 2019 04:49 pm ET
Aurinia to Hold Conference Call and Webcast to Discuss Results of Phase 2 Head-to-Head Study of Voclosporin Ophthalmic Solution versus Restasis® for the Treatment of Dry Eye Syndrome
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced it will report results before the opening of trading and hold a webcast and conference call to discuss the results of its Phase 2, double-masked, head-to-head study of VOS 0.2% versus Restasis® (cyclosporine ophthalmic emulsion 0.05%) to evaluate the efficacy, safety and tolerability at four weeks in subjects with dry eye syndrome (DES).
Dec 19, 2018 08:00 am ET
Aurinia to Present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco
Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced its Chairman and Chief Executive Officer, Richard M. Glickman, will present a company overview at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Thursday, January 10, 2019 at 10:00am PST, 1pm EST.
Nov 30, 2018 05:18 pm ET
Aurinia Establishes at-the-Market Facility
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”) today announced that it has entered into an Open Market Sale Agreement (the “Sale Agreement”) with Jefferies LLC (“Jefferies”) pursuant to which the Company may from time to time sell, through at-the-market (“ATM”) offerings with Jefferies acting as sales agent or directly to Jefferies acting as principal, such common shares in the capital of the Company (“Common Shares”) as would have an aggregate offering price of up to U
Nov 09, 2018 07:00 am ET
Aurinia to Participate in November Investor Conferences
Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced its Chairman and CEO, Richard Glickman, will participate in two upcoming investor conferences.
Nov 08, 2018 04:02 pm ET
Aurinia Reports Third Quarter Financial Results, Clinical Highlights and Corporate Development
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”) has released its financial results for the third quarter ended September 30, 2018. Amounts, unless specified otherwise, are expressed in U.S. dollars.
Oct 25, 2018 07:00 am ET
Aurinia Pharmaceuticals to Release Third Quarter Financial Results and General Business Updates on November 8, 2018
Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH) (TSX:AUP) today announced that it will release its third quarter 2018 financial results on Thursday, November 8, 2018, after the market closes. Aurinia’s management will host a conference call to discuss the company’s third quarter 2018 financial results and provide a general business update.
Sep 25, 2018 04:01 pm ET
Aurinia Completes Enrollment of AURORA, its Phase 3 Clinical Trial for the Treatment of Lupus Nephritis
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH/TSX:AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced that it has completed enrollment for the AURORA Phase 3 trial ahead of schedule. The target enrollment of 324 patients was surpassed due to high patient demand with 358 lupus nephritis (LN) patients randomized in sites across 27 countries.
Sep 19, 2018 04:01 pm ET
Aurinia to Participate in Upcoming Investor Conferences
Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced its Chairman and CEO, Richard Glickman, will present a company overview at two upcoming investor conferences.
Aug 28, 2018 07:00 am ET
Aurinia Announces Participation at the 20th Annual Global Investment Conference in New York City September 4-6, 2018
Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced it will be featured as a presenting company at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 4-6, 2018 at the St. Regis New York Hotel in New York City.
Aug 09, 2018 04:02 pm ET
Aurinia Reports Second Quarter Financial Results and Operational Highlights
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”) has released its financial results for the second quarter ended June 30, 2018. Amounts, unless specified otherwise, are expressed in U.S. dollars.
Jul 30, 2018 04:20 pm ET
Aurinia Pharmaceuticals to Release Second Quarter 2018 Financial Results on August 9, 2018
Aurinia Pharmaceuticals Inc., (NASDAQ: AUPH / TSX: AUP) today announced that it will release its second quarter 2018 financial results on Thursday, August 9, 2018, after the market closes. Aurinia’s management will host a conference call to discuss the company’s second quarter 2018 financial results and provide a general business update.
Jul 11, 2018 04:01 pm ET
Aurinia Initiates Phase 2 Clinical Trial for Voclosporin Ophthalmic Solution for the Treatment of Dry Eye Syndrome
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH/TSX: AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced the initiation of its Phase 2 trial evaluating voclosporin ophthalmic solution (VOS) for the treatment of dry eye syndrome (DES).
Jun 25, 2018 07:00 am ET
Aurinia Initiates Clinical Trials Broadening the Development of Voclosporin
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced the enrollment of the first patients into the AURORA 2 extension study in lupus nephritis and the initiation of its Phase II trial in focal segmental glomerulosclerosis (FSGS).
Jun 22, 2018 04:30 pm ET
Aurinia Announces Results of Annual General Meeting
Aurinia Pharmaceuticals Inc. (“Aurinia” or the “Company”) (NASDAQ: AUPH / TSX: AUP) is pleased to announce that the eight incumbent directors of the Company were elected at the Company’s annual general meeting held on June 21, 2018 (the “Meeting”).
May 10, 2018 04:02 pm ET
Aurinia Reports First Quarter Financial Results and Operational Highlights
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”) has released its financial results for the first quarter ended March 31, 2018. Amounts, unless specified otherwise, are expressed in U.S. dollars.
May 10, 2018 08:00 am ET
Aurinia Pharmaceuticals Recognizes World Lupus DayTM with Activities Focused on Raising Awareness of Lupus Nephritis
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced its support for World Lupus DayTM with activities focused on raising awareness of lupus nephritis (LN). In honor of the day, Aurinia is collaborating with The Mighty,
May 01, 2018 04:23 pm ET
Aurinia Pharmaceuticals to Release First Quarter 2018 Financial Results on May 10, 2018
Aurinia Pharmaceuticals Inc., (NASDAQ: AUPH / TSX: AUP) today announced that it will release its first quarter 2018 financial results on Thursday, May 10, 2018, after the market closes. Aurinia’s management will host a conference call to discuss the company’s first quarter 2018 financial results and provide a general business update.
Apr 25, 2018 04:01 pm ET
Aurinia to Present at the Bloom Burton & Co. Healthcare Investor Conference on May 3, 2018
Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced that Celia Economides, Vice President, Corporate and Public Affairs, will present at the Bloom Burton & Co. Healthcare Investor Conference on Thursday, May 3rd at 1:30pm EDT. A webcast will be available and can be accessed via the investor section of the Aurinia website,
Apr 02, 2018 04:01 pm ET
Aurinia Announces Participation at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo, Monaco on April 8-10, 2018
Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced it will be featured as a presenting company at the H. C. Wainwright Annual Global Life Sciences Conference. The conference is being held on April 8-10 at the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco.
Mar 15, 2018 04:02 pm ET
Aurinia Reports Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”) has released its financial results for the fourth quarter and year ended December 31, 2017. Amounts, unless specified otherwise, are expressed in U.S. dollars.
Feb 28, 2018 04:02 pm ET
Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year 2017 Financial Results on March 15, 2018
Aurinia Pharmaceuticals Inc., (NASDAQ: AUPH / TSX: AUP) today announced that it will release its fourth quarter and full year 2017 financial results on Thursday, March 15, 2018, after the market closes. Aurinia’s management will host a conference call to discuss the company’s financial results for the fourth quarter and full year 2017 and provide a general business update.
Feb 22, 2018 04:07 pm ET
Aurinia Enhances Research, Development, and Scientific Expertise with the Appointment of Michael Hayden to its Board of Directors
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced the appointment of Michael Hayden, CM OBC MB ChB PhD FRCP (C) FRSC to its board of directors. Dr. Hayden was most recently the President of Global R&D and Chief Scientific Officer at Teva.
Feb 20, 2018 04:01 pm ET
Aurinia Named Company of the Year by LifeSciences BC
Aurinia Pharmaceuticals Inc., (NASDAQ: AUPH / TSX: AUP) today announced it has received this year’s Company of the Year Award from LifeSciences BC. The 2018 LifeSciences BC award winners will be recognized at this year’s annual dinner presented by FARRIS, held on April 19, 2018 in Vancouver.
Feb 14, 2018 08:00 am ET
Aurinia Pharmaceuticals Launches New Lupus Nephritis Disease Awareness Program
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP) (“Aurinia” or the “Company”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced that it has launched ALL INTM, an educational program for people living with lupus nephritis (LN). ALL IN is designed to raise awareness for LN and to support members of the LN community.
Feb 08, 2018 08:00 am ET
Aurinia Enhances Commercial and Business Development Expertise with the Appointment of Joseph P. Hagan to its Board of Directors
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced the appointment of Joseph P. “Jay” Hagan. to its board of directors. Mr. Hagan is currently the President and Chief Executive Officer of Regulus Therapeutics.
Feb 06, 2018 08:00 am ET
Aurinia to Present at Leerink Partners 7th Annual Global Healthcare Conference
Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced that its Chief Executive Officer, Richard M. Glickman and Celia Economides, Vice President, Corporate and Public Affairs, will participate in a Fireside Chat at the Leerink Partners 7th Annual Global Healthcare Conference on February 14th at 2:30pm ET. A webcast will be available and can be accessed via the investor section of the Aurinia website,
Jan 04, 2018 04:37 pm ET
Aurinia Pharmaceuticals Files New Preliminary Base Shelf Prospectus to Replace Expired Base Shelf Prospectus
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”) today announced that in order to replace its prior expired base shelf prospectus and corresponding shelf registration statement it has filed a preliminary short form base shelf prospectus (the “Preliminary Shelf Prospectus”) with the securities commissions in each of the provinces of Ontario, Alberta and British Columbia in Canada, and a corresponding shelf registration statement on Form F-10 with the U.S. Securities and Exchange Commission (
Dec 11, 2017 04:02 pm ET
Aurinia Pharmaceuticals Added to the NASDAQ Biotech Index
Aurinia Pharmaceuticals Inc., (NASDAQ: AUPH / TSX: AUP) announced today that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq:^NBI), which will become effective prior to market open on Monday, December 18, 2017.
Nov 14, 2017 04:00 pm ET
Aurinia Reports Third Quarter 2017 Financial Results and Provides Operational Highlights
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”) has released its financial results for the third quarter ended September 30, 2017. Amounts, unless specified otherwise, are expressed in U.S. dollars.
Nov 06, 2017 04:05 pm ET
Aurinia Pharmaceuticals to Release Third Quarter 2017 Financial Results on November 14, 2017
Aurinia Pharmaceuticals Inc., (NASDAQ: AUPH / TSX: AUP) today announced that it will release its third quarter 2017 financial results on Tuesday, November 14, 2017, after the market closes. At 4:30 p.m. Eastern Time Aurinia’s management will host a conference call to discuss the company’s financial results for the third quarter 2017 and provide a general business update.
Oct 20, 2017 08:00 am ET
Aurinia to Expand Renal Franchise with Novel Indications and Launches Development Program for Treatment of Dry Eye Syndrome
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia) today announced plans to expand its voclosoprin renal franchise to include focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD). Additionally, Aurinia announced plans to evaluate its proprietary nanomicellar voclosporin ophthalmic solution (VOS) for the treatment of keratoconjunctivitis sicca or dry eye syndrome (DES). The advancement of these new indications, in addition to lupus nephritis (LN), represents an expansion of the company’s strategy, pipeline and
Oct 12, 2017 07:00 am ET
Aurinia Receives National Corporate Visionary Award from the Lupus Foundation of America
Aurinia Pharmaceuticals Inc., (NASDAQ: AUPH / TSX: AUP) today announced it has received this year’s National Corporate Visionary Award from the Lupus Foundation of America. The award was presented to Dr. Richard and Michelle Glickman and to Aurinia for its long-term commitment to advancing treatments for lupus and lupus nephritis. The award was presented yesterday evening during the Foundation’s Annual Evening of Hope Gala in New York City.
Sep 08, 2017 06:15 pm ET
S&P Dow Jones Indices Announces Changes to the S&P/TSX Canadian Indices
The Annual Review of the S&P/TSX SmallCap Index
Nov 03, 2016 09:07 am ET
IIROC Trade Resumption - AUP
TORONTO, Nov. 3, 2016 /CNW/ - Trading resumes in:
Nov 02, 2016 05:56 pm ET
IIROC Trading Halt - AUP
TORONTO, Nov. 2, 2016 /CNW/ - The following issues have been halted by IIROC:
Sep 30, 2016 09:01 am ET
IIROC Trade Resumption - AUP
TORONTO, Sept. 30, 2016 /CNW/ - Trading resumes in:
Sep 29, 2016 05:45 pm ET
IIROC Trading Halt - AUP (all issues)
TORONTO, Sept. 29, 2016 /CNW/ - The following issues have been halted by IIROC:

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.